Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman

References

• Cannon CP, Braunwald E, McCabe CH, et al. Intensive vs. moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the “good” still count? Atherosclerosis 2005;180:217-23
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get with the Guidelines. Am Heart J 2009;157:111-17
   PubMed Web of Science ®Google Scholar
• Alshejkh-Ali AA, Lin JL, Abourjally P, et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007;100:1499-501
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49-55
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Assmann G, Fruchart JC, et al. European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high- density lipoprotein cholesterol levels. Heart 2008;94:706-14
   PubMed Web of Science ®Google Scholar
• Zubaid M, Rashed WA, Al-Khaja N, et al. Clinical presentation and outcomes of acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Saudi Med J 2008;29:251-5
   PubMed Web of Science ®Google Scholar
• Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001;38:2114-30
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Scott M, et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome. J Atheroscler Thromb 2010;17:1096-107
   PubMed Web of Science ®Google Scholar
• Wolfram M, Brewer HB, Roswitha ZX, et al. Impact of low high-density lipoproteins on in hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol 2006;98:711-17
   PubMed Web of Science ®Google Scholar
• Kini AS, Muntner P, Moreno PR, et al. Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl. Am J Cardiol 2009;103:350-4
   PubMed Web of Science ®Google Scholar
• Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular mortality in middle-aged men. JAMA 2002;288:2709-16
   PubMed Web of Science ®Google Scholar
• Al-Rasadi K, Sulaiman K, Panduranga P, et al. Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients from Oman. Angiology 2010; in press
   Google Scholar
• Davidson MH: Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 2005;96:3-13K. Discussion 34-35K
   Google Scholar
• Shepherd J, Barter P, Carmena R, et al. for the Treating to New Targets Investigators. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
   PubMed Web of Science ®Google Scholar
• Roe MT, Ou FS, Alexander KP, et al. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2008;29:2480-8
   PubMed Web of Science ®Google Scholar
• Pintó X, Millán J, Muñoz AA, et al. A very high prevalence of low HDL cholesterol in Spanish patients with acute coronary syndromes. Clin Cardiol 2010;33:418-23
   PubMed Web of Science ®Google Scholar
• Chiesa G, Parolini C, Sirtori CR. Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Curr Opin Cardiol 2008;23:379-85
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2007;50:e1-157
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB, et al. National Heart, Lung, Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009. Can J Cardiol 2009;25:567-79
   PubMed Web of Science ®Google Scholar
• Pfohl M, Schreiber I, Liebich HM, et al. Upregulation of cholesterol synthesis after acute myocardial infarction is cholesterol a positive acute phase reactant? Atherosclerosis 1999;142:389-93
   PubMed Web of Science ®Google Scholar
• Pitt B, Loscalzo J, Ycas J, et al. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008;51:1440-5
   PubMed Web of Science ®Google Scholar
• Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systemic review and meta-regression analysis. BMJ 2009;338:b92
   PubMed Web of Science ®Google Scholar
• Jaafri H, Alsheikh-Ali A, Karas RH. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153:800-8
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Mikhailidis DP. The DEFINE study: a bright future for CETP inhibitors? Expert Opin Investig Drugs. 2011 Jan 17 [Epub ahead of print]
   Google Scholar